National Health (Pharmaceutical benefits supplied under subsection 93A(4)) Determination 2012 (No. PB 50 of 2012)

Overview

The National Health (Pharmaceutical benefits supplied under subsection 93A(4)) Determination 2012 (PB 50 of 2012) was enacted in 2012 under regulation 37AA of the National Health (Pharmaceutical Benefits) Regulations 1960, pursuant to the National Health Act 1953. This legislation was introduced to address the specific issue of providing pharmaceutical benefits to patients in prescribed institutions, such as residential care services as defined under the Aged Care Act 1997. The primary objective of the Determination is to ensure that the payment rates for these pharmaceutical benefits are adequately set and that the conditions under which they are supplied are clearly outlined. The enactment of this Determination by the Australian Government, specifically the Department of Health and Ageing, aims to establish a fair and efficient system for the provision of essential medications to patients in such institutions, ensuring that they receive the necessary treatment without undue financial burden.

Scope and Application

The National Health (Pharmaceutical benefits supplied under subsection 93A(4)) Determination 2012, also referred to as PB 50 of 2012, applies to the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners to prescribed institutions under the National Health Act 1953. Specifically, the Determination sets out the rate of payment made by the Commonwealth for such pharmaceutical benefits, with the rate being the amount by which the Commonwealth price exceeds the patient co-payment, plus any special patient contribution where applicable. The Determination also applies conditions determined by the Minister under the Act to the payment for these pharmaceutical benefits. The Determination came into effect on 1 July 2012, and a prescribed institution under the Act is a residential care service as defined in the Aged Care Act 1997. The scope of the Determination is limited to the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners to prescribed institutions, as outlined in the Act and Regulations. The Determination does not extend to other types of pharmaceutical benefits or supplies. While the Determination itself does not contain exclusions, exemptions, or thresholds, the National Health Act and Regulations may contain provisions that limit or exclude certain benefits or supplies. The application of the Determination may also be extended or restricted through subordinate instruments made under the Act or Regulations.

Key Provisions

The National Health (Pharmaceutical benefits supplied under subsection 93A(4)) Determination 2012 (PB 50 of 2012) sets out the rate of payment by the Commonwealth for pharmaceutical benefits supplied by approved pharmacists or approved medical practitioners to prescribed institutions, such as residential care services (section 4). The rate of payment is determined by the amount that the Commonwealth price for the supply of the pharmaceutical benefit exceeds the patient co-payment, plus any special patient contribution if applicable (section 4). This Determination also specifies the conditions under which payment is made to these approved suppliers for the supply of pharmaceutical benefits to prescribed institutions (section 5). The Determination imposes several obligations on approved pharmacists and approved medical practitioners. Firstly, they must ensure that the pharmaceutical benefits supplied to prescribed institutions meet the criteria set out in the Determination (section 4). Secondly, they must adhere to the patient co-payment and special patient contribution provisions, ensuring that these are correctly calculated and charged in accordance with the Act and Regulations (section 4). Approved pharmacists and approved medical practitioners must also comply with any conditions determined by the Minister for the supply of pharmaceutical benefits to prescribed institutions (section 5). Failure to comply with the provisions of the Determination may result in various consequences. While the Determination does not explicitly outline specific offences or penalties, non-compliance with the National Health Act 1953 or the National Health (Pharmaceutical Benefits) Regulations 1960 may lead to enforcement actions under those Acts. This could include financial penalties, legal proceedings, or other sanctions as provided for in the primary legislation. The maximum penalties for offences under the National Health Act 1953 can be substantial, depending on the nature and severity of the breach.